• What are the Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis?

What are the Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis?

Vitamin K antagonists (VKAs) increase risk of minor bleeding in patients with cirrhosis given anticoagulants for portal vein thrombosis (PVT), compared to patients without cirrhosis given VKAs, researchers report in the July issue of Clinical Gastroenterology and Hepatology. However, this risk is offset by the ability of VKA to increase portal

Read more
  • Does an SVR to Therapy for HCV-associated Cirrhosis Reduce Portal Pressure?

Does an SVR to Therapy for HCV-associated Cirrhosis Reduce Portal Pressure?

A sustained virologic response (SVR) to all-oral therapy in patients with hepatitis C virus (HCV)-associated cirrhosis significantly reduces the hepatic venous pressure gradient (HVPG), researchers report in the November issue of Gastroenterology. Nevertheless, almost 80% of patients maintain significant portal hypertension and have a continued risk of decompensation. In patients with compensated

Read more

Can Circulating Membrane Vesicles Promote Portal Hypertension?

Patients with cirrhosis have a large amount of circulating membrane vesicles—breakdown products from inflammation and liver cell damage. However, these ‘microparticles’ (MPs) are not simply debris; they contribute to the systemic vasodilation and portal hypertension associated with cirrhosis, according to the July issue of Gastroenterology. Patients with cirrhosis have persistent

Read more